Gilead Sciences is a global biopharma company with diverse portfolio and is known for its infectious disease drug portfolio.
| Molecule | Target | Phase | Indication | NCT Number | Mol Type |
|---|---|---|---|---|---|
| Sacituzumab / GS-0132 / IMMU-132 | trop2 | III | Metastatic Urothelial Carcinoma | NCT04527991 | Monoclonal Antibody |
| Magrolimab / GS-4721 / 5F9 / Hu5F9-G4 | CD47 | III | Myelodysplastic Syndrome | NCT04313881 | Monoclonal Antibody |
| III | Acute Myeloid Leukemia | NCT04778397 | |||
| II | Solid Tumor | NCT04827576 | |||
| I/II | Non Hodgkin Lymphoma | NCT02953509 | |||
| Zimberelimab / GS-0122 / AB122 | PD1 | III | Non Small Cell Lung Cancer | NCT04736173 | Monoclonal Antibody |
| GS-1423/ AGEN 1423 | CD73/TGFβ Trap | I | Advanced Solid Tumors | NCT03954704 | Bispecific Antibody |
| GS-4224 | PD-L1 | I/II | Advanced Solid Tumors | NCT04049617 | Small Molecule |
| Filgotinib / GS-3583 | Flt3R | I | Advanced Solid Tumors | NCT04747470 | Small Molecule |
| GS-0189 | SIRP-a | IND | Advanced Solid Tumors | Small Molecule |
Gilead Sciences Active Oncology Pipeline Drug Description
- Magrolimab /Hu5F9-G4 is a humanized monoclonal antibody against human CD47. CD47 is overexpressed on the surface of the majority of tumors and transmits a “don’t eat me” signal, enabling cancer cells to evade phagocytosis by macrophages.
- In preclinical models, Hu5F9-G4 facilitated phagocytosis and elimination of cancer cells from multiple human tumor types as a monotherapy. Additionally, when used in combination therapy, it engaged macrophages as effector cells to enhance the efficacy of cancer-specific antibodies via Antibody-Dependent Cellular Phagocytosis (ADCP).
- Magrolimab has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of MDS and AML, and for the treatment of relapsed or refractory DLBCL and follicular lymphoma, two forms of B-cell NHL. Magrolimab has also been granted Orphan Drug designation by the FDA for the treatment of MDS and AML and by the European Medicines Agency for the treatment of AML.
- Zimberelimab / AB122 potently and selectively blocks this interaction between PD-1 and its ligands, and is currently in a Phase 1 trial in cancer patients and is also in Phase 1/2 clinical evaluation in combination with AB928 from the second quarter of 2018.
- Invented by Agenus, licensed to Gilead, GS-1423 (previously AGEN 1423), is a bispecific, checkpoint modulating antibody, being developed by Agenus, for the treatment of cancer.
Page 2 of 2
